Considering�how difficult the lending environment is for mid-size private companies, it only makes sense to take a hard look at the business development companies (BDCs).
It’s been a catch 22 for the banks. They are awash in cash,� but after getting shell shocked by the recession they aren’t willing to put that cash in the system in the form of new small-business loans as the Fed had intended under its current policy.
Hot High Dividend Companies To Own For 2015: PURE Bioscience Inc.(PURE)
Pure Bioscience, Inc. engages in the discovery, development, and commercialization of bioscience products principally in the United States. The company offers silver dihydrogen citrate (SDC) based antimicrobials. The silver dihydrogen citrate technology is an electrochemical process that allows the generation of ionized silver in the presence of organic acid. It provides PURE Hard Surface, a hard surface disinfectant and food contact surface sanitizer for use in food processing equipment, machinery, and utensils; Axen30, a hard surface disinfectant; Silv�ion, an antimicrobial formulation used as a raw material in the manufacturing of personal care products; and Axenohl, an antimicrobial formulation for use as a raw material in the manufacturing of environmental protection agency-registered products. The company also offers research and development services in food processing, agriculture, water treatment, pharmaceuticals, and oil and gas projects. It sells its products t hrough partners and distributors primarily to industrial and consumer markets. The company, formerly known as Innovative Medical Services, was founded in 1992 and is headquartered in El Cajon, California.
Advisors' Opinion:- [By Glenwoods]
While the fermentation-based method is still in its development stages, a Malaysian company, PureCircle (LON: PURE) (OTCMKTS: PCRTF), the world�� largest producer of stevia, continues to develop its stevia through farm-based methods.� Last September PureCircle, which also has offices in Oak Brook, Ill., signed a joint agreement with the Coca-Cola Coto investigate and develop a commercially viable stevia sweetener product; and earlier this month in a press release, the two companies announced they were developing what should be a better flavor profile than the much used Reb A with rebaudioside D (Reb D) and Rebaudioside X (Reb X).� Reb D, though roughly 10% less sweet than Reb A, has a significantly lower bitterness that Reb A and has been found to have a more desirable taste profile, especially in cola products where stevia previously has not worked well.� The issue with both Reb D and Reb X is that they are found in much smaller amounts than Reb A. Thus, at this time it will take a lot more stevia leaves to produce the extracts.
- [By Glenwoods]
According to the global market research company Mintel, stevia-based products have increased 400% globally between 2008 and 2012, with a rise of 158% from 2011 to 2012. Stevia has grown so much in demand that the world�� largest alfalfa grower, California-based S&W Seed (SANW), began growing stevia with high glycoside yields for PureCircle (LN:PURE), the world�� largest producer of stevia, in 2011 and on roughly 250,118 acres. Now some U.S. tobacco farmers have begun to switch from growing tobacco to stevia, as tobacco sales are sliding and stevia sales are growing.
Hot High Dividend Companies To Own For 2015: Renegade Petroleum Ltd (RPL)
Renegade Petroleum Ltd. (Renegade) is an exploitation and exploration focused light oil producer. Renegade's primary focus areas are located in southeast Saskatchewan in various pools, such as Bakken, Souris Valley, Frobisher, Midale and Kisby, as well as the Dodsland area of the Viking play in west-central Saskatchewan. It also has working interests in North Dakota pursuant to a farm-in agreement respecting land in Renville County that is prospective for Bakken, Threeforks/Sanish and Frobisher light oil. In addition the Company has a light oil opportunity in the Spearfish play in Manitoba. It has two geographic segments: western Canada and the State of North Dakota, the United Sates. In December 2012, the Company acquired certain strategic light oil assets. In February 2014, the Company closed the disposition of certain oil and gas assets in southeast Saskatchewan. Advisors' Opinion:- [By John Udovich]
Many American oil and gas investors are probably familiar with the major large and small cap players in the Bakken formation in North Dakota and Montana, but few American investors are probably familiar with�the active players further to the north in the�oil and gas rich Canadian provinces of Saskatchewan and Alberta�with small cap stocks like Alexander Energy Ltd (CVE: ALX), Renegade Petroleum Ltd (CVE: RPL) and Centor Energy Inc (OTCBB: CNTO) along with large cap Suncor Energy Inc (NYSE: SU) being among those�pumping out their share of noteworthy news lately. I should point out that�Canada�� oil reserves are ranked #3 after to Venezuela and Saudi Arabia with over 95% of these reserves being the controversial�oil sands of Alberta while the neighboring province of Saskatchewan (which the Bakken formation actually stretches into) along with offshore areas of Newfoundland also containing substantial production and reserves. Moreover and excluding the oil sands, Alberta would have 39% of Canada�� remaining conventional oil reserves,�followed by�offshore Newfoundland with�28% and Saskatchewan with 27%.
5 Best International Stocks To Watch Right Now: Acorn Energy Inc.(ACFN)
Acorn Energy, Inc., through its subsidiaries, provides technology driven solutions for energy infrastructure asset management worldwide. It offers sonar and acoustic related solutions for energy, defense, and commercial markets with a focus on underwater site security for strategic energy installations and other acoustic systems, as well as develops and produces real-time embedded hardware and software. The company also develops and markets remote monitoring systems to electric utilities and industrial facilities, which are used in a range of utility applications, including outage management, power quality monitoring, system planning, trouble shooting and proactive maintenance, and condition monitoring; and provides the intelligence to transmission and distribution network operators. In addition, it develops and produces fiber optic sensing systems for the energy, commercial security, and defense markets. The company?s patented ultra-high sensitivity fiber optic sensors a re designed to replace electronic sensors with fiber optic sensors. Further, it engages in the design, manufacture, marketing, and sale of wireless remote systems that monitor standby power generation, backup power generators, remote powered equipment, cellular towers, emergency towered communications, and remote tower sites; cathodic protection products to monitor pipeline integrity; and other wireless remote systems. Acorn Energy, Inc. was founded in 1986 and is based in Montchanin, Delaware.
Advisors' Opinion:- [By Roberto Pedone]
A technology stock that's starting to move within range of triggering a big breakout trade is Acorn Energy (ACFN), which provides digital solutions for energy infrastructure asset management. This stock has been hit hard by the sellers in 2013, with shares off sharply by 48%.
If you take a look at the chart for Acorn Energy, you'll notice that this stock has started to spike higher here back above its 50-day moving average of $3.66 a share. This stock has also found significant buying interest over the last two months, each time it has pulled back to around $3.50 to $3.20 a share. Shares of ACFN are now quickly moving within range of triggering a big breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in ACFN if it manages to break out above some key near-term overhead resistance levels at $4.24 to $4.64 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 344,835 shares. If that breakout triggers soon, then ACFN will set up to re-test or possibly take out its next major overhead resistance levels at $5.50 to $6 a share. Any high-volume move above $6 will then put its next major overhead resistance levels at its 200-day moving average of $6.35 to $6.68 a share into range for shares of ACFN.
Traders can look to buy ACFN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $3.66 a share, or right around some major support at $3.21 a share. One could also buy ACFN off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot High Dividend Companies To Own For 2015: SP Bancorp Inc.(SPBC)
SP Bancorp, Inc. operates as the holding company for SharePlus Federal Bank that provides community banking products and services to individuals, families, and businesses in the United States. The company offers various deposit products, including noninterest-bearing and interest-bearing demand accounts, savings accounts, money market accounts, and certificates of deposit. Its loan portfolio includes residential mortgage loans secured by residential real estate; commercial real estate and home equity loans, including lines of credit and home improvement loans; consumer loans consisting primarily of automobile loans; and commercial business loans. The company also provides brokerage services for the purchase and sale of non-deposit investment and insurance products through a third-party brokerage arrangement. It provides its services through seven branches, four of which are located near the Bank's headquarters in Plano, Texas; two branches are located in Louisville, Kentuc ky; and one branch is located in Irvine, California. The company was founded in 2010 and is headquartered in Plano, Texas.
Advisors' Opinion:- [By Lisa Levin]
SP Bancorp (NASDAQ: SPBC) shares touched a new 52-week high of $28.90 after the company agreed to be acquired by Green Bancorp for $46.2 million in cash.
Hot High Dividend Companies To Own For 2015: Arris Group Inc(ARRS)
Arris Group, Inc. develops, manufactures, and supplies telephony, data, video, construction, rebuild, and maintenance equipment for the broadband communications industry worldwide. The company operates in three segments: Broadband Communications Systems (BCS); Access, Transport, and Supplies (ATS); and Media and Communications Systems (MCS). The BCS segment provides VoIP and high speed data products, including CMTS edge routers, 2-line residential EMTA, multi-line EMTA for residential and commercial services, wireless gateway, and high speed data cable modems; video/IP products comprising CMTS edge routers, broadband and universal EdgeQAM, and whole home gateway and media players; and video processing products, such as switched digital video systems, digital video encoders, transcoders, transraters, and statistical multiplexers. The ATS segment offers hybrid fiber-coaxial plant equipment products comprising headend and hub products, optical transmitters, optical amplifiers , optical repeaters, optical nodes, WiFi access points, ePON optical network units and line terminals, RF over glass optical network units, and radio frequency amplifiers; and infrastructure products for fiber optic or coaxial networks, which include cable and strand, vaults, conduit, drop materials, tools, connectors, and test equipment. The MCS segment provides media, delivery, and monetization platform products, such as video on demand management and distribution, and linear and advanced advertising; operations management systems comprising network and service assurance, and mobile workforce management; and fixed mobile convergence platform products, such as mobility application servers for continuity of services in wireless and PacketCable networks, and voice call continuity application servers for continuity of services in IP multimedia subsystem networks. The company offers its services to cable system operators. Arris Group, Inc. was founded in 1969 and is headquarter ed in Suwanee, Georgia.
Advisors' Opinion:- [By Tess Stynes var popups = dojo.query(".socialByline .popC"); popups.forEach(fu]
Cable-equipment maker Arris Group Inc.(ARRS) posted a strong forecast for the current quarter and better-than-expected results for the first three months of the year. Shares rose 14% to $29.27 premarket.
- [By Evan Niu, CFA]
Google also sold off the Motorola Home business to Arris� (NASDAQ: ARRS ) in a $2.4 billion cash and stock deal, which closed this month. Big G is now the proud owner of a 7.7% stake in Arris, while its net cost for Motorola subsequently declined to around $7.1 billion.
- [By Lee Jackson]
Arris Enterprises Inc. (NASDAQ: ARRS) got hit when press reports indicated that Apple may be working with Time Warner Cable and other companies on a new set-top box. The Jefferies team do not know the specifications of the device. It still may use “HDMI pass through” architecture like XBox One (and therefore will still require a cable STB to support cable content). That would bode well for Arris. The Jefferies target is lifted to $30. The Thomson/First Call estimate is $28.05. Arris closed on Friday at $27.87.
Hot High Dividend Companies To Own For 2015: ForeverGreen Worldwide Corp (FVRG)
ForeverGreen Worldwide Corporation, incorporated on March 18, 1999, is a holding company that operates through its wholly owned subsidiary, ForeverGreen International, LLC. The Company's product philosophy is to develop, manufacture and market the science and nature through formulations as the Company produces and manufacture a wide arrays of whole foods, nutritional supplements, personal care products and essential oils. The Company provides health answers, not only through exclusive nutritional whole food beverages, but also by providing a broad product lines of delicious whole foods that can be eaten for every meal, instead of the processed, fatty and preservative-laden synthetic meals prevalent in society.
The Company provides the every-meal answer with a variety of appetizing healthy food products that allow its Members and customers to eat healthy for every meal and snack throughout the day. In addition, the Company provides healthy personal care products as an alternative to the chemical-laden and synthetic products in the marketplace that may potentially negatively impacts its health. The Company's products, along with a distinct and fresh corporate philosophy and message of physical, mental, emotional and spiritual health through service to community and others, attract consumers as well as Members who wish to own a home-based business selling the Company's products and spreading its health message.
The Company's primary product is FrequenSea, a whole-food beverage consisting of a blend of marine phytoplankton, ionic sea minerals, frankincense, rose, ginger and aloe vera in a base of blueberry, cranberry and lime juice concentrate. soluble. FrequenSea is sold as a single bottle, in individual single-serving packets or even in four-bottle packs. The marine phytoplankton in FrequenSea contains more than 200 different sea algae that are all processed through patent-pending harvesting processes. Azul is a rich-in-antioxidant, delicious powdered blend of 24 raw whole foo! d and fruit ingredients and probiotics that are naturally dried and blended to preserve their natural integrity.The Company's whole food offerings consist of a variety of healthy, natural food products that are made onsite in the Company's whole-food manufacturing facility. Versativa Pulse based with hemp seed, consists of 17 different nuts, seeds, fruits, grains and other whole foods. Pulse is offered in various flavors, either loose in bags or in snack bars, and may be used as a snack or a meal replacement.
The Company competes with NuSkin, Neways, Young Living Essential Oils, Amway Corporation, Herbalife and NuSkin Enterprises.
Advisors' Opinion:- [By CRWE]
Last Friday, FVRG had shed (-15.38%) down -0.100 at $.550 with 20,050 shares in play at the close (ref. google finance August 16, 2013 ��Close).
ForeverGreen Worldwide Corporation previously reported that sales are continuing to flourish. Sales for July 2013 increased to in excess of $1.44 million compared to $1.04 million during July 2012, an increase of 38.1%. Sequentially, sales increased 12.3% compared to June 2013.
Hot High Dividend Companies To Own For 2015: Virco Manufacturing Corporation(VIRC)
Virco Mfg. Corporation engages in the design, production, and distribution of furniture for the commercial and education markets in the United States. The company offers seating products, including cantilever chairs, tablet arm chairs, rockers, hard plastic seats, backrests, work surfaces, task chairs, classroom chairs, stack chairs, folding chairs, upholstered stack chairs, plastic stack chairs, and upholstered ergonomic chairs, as well as provides various seating product for students in college, university, other adult education settings, and on high school campuses. It also offers folding and banquet tables, activity tables, office tables, computer tables, and mobile tables, as well as table products for working and learning environments, seminars, and conferences; and computer furniture, including keyboard mouse trays, CPU holders, support columns, desks and workstations, and specialty tables and other products for computing applications. In addition, the company provi des chair desks, combo units, teacher desks, and tablet arm units, as well as a collection returns and credenzas. Further, it offers administrative office furniture, such as desks, returns, and bookcases; laboratory furniture, including steel-based science tables, table bases, lab stools, and steel foot-rings for biology and chemistry classes, and other school and college based lab settings; and mobile furniture comprising mobile tables for school cafeterias and mobile chairs for school settings and offices, as well as provides handling and storage equipment and manufactures stackable storage trucks. The company?s brand portfolio primarily includes ZUMA, ZUMAfrd, Ph.D., I.Q. Virtuoso, Classic Series, Martest 21, Lunada, Plateau, Core-a-Gator, Future Access, Sigma, Metaphor, Telos, TEXT, and Parameter. It also serves convention centers and arenas, hospitality providers, government facilities, and places of worship. Virco Mfg. Corporation founded in 1950 and is based in Torra nce, California.
Advisors' Opinion:- [By John Udovich]
Small cap office furniture stock Steelcase Inc (NYSE: SCS) jumped 11.66% after beating earnings expectations, meaning it might be time to take a closer look at the stock along with potential office or commercial furniture stock peers like�HNI Corp (NYSE: HNI), Knoll Inc (NYSE: KNL) and Virco Mfg. Corporation (NASDAQ: VIRC). After all, the performance of any company selling office or commercial furniture would tend to give some insights into the office or employment markets.
Hot High Dividend Companies To Own For 2015: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Victor Selva]
Forest Laboratories Inc. (FRX) is one of the largest U.S.-based pharmaceutical companies in the area of developing, producing and selling central nervous system (CNS)-related prescription drugs. The company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners.
- [By Lisa Levin]
Furiex Pharmaceuticals (NASDAQ: FURX) shares moved up 28.41% to $102.92. The volume of Furiex Pharmaceuticals shares traded was 2285% higher than normal. Forest Labs (NYSE: FRX) announced its plans to buy Furiex Pharma for up to $1.46 billion.
- [By Eric Volkman]
Forest Laboratories (NYSE: FRX ) now has a significant research project on its plate -- finding the company's next CEO. The current occupant of that position, Howard Solomon, is to retire at the end of this year. He will remain as chairman of the firm until its annual general meeting, after which he will hold the title of chairman emeritus.
- [By Johanna Bennett]
Two months since becoming chief executive at Forest Laboratories (FRX), and Brenton Saunders is putting his mark on the drug maker.
On Monday, Forest outlined ��roject Rejuvenate,��a plan to cut costs $500 million by 2016, while scaling back research and development efforts and reducing the company�� work force.
It�� been a common story among big pharmaceutical companies. The industry has grown to depend on acquisitions and licensing deals or partnerships with small drug makers rather than in-house efforts to produce the blockbuster products needed to grow sales and offset revenue lost to generic rivals.
Investors seem to approve. At $55.54, the stock surged 8.2% during afternoon market action.
It was actually a pretty busy day for Forest. Though it restructuring plans attracted the most attention, the company also announced the sale of $1 billion of new debt to help fund $400 million in accelerated stock buybacks as part of a larger $1 billion share repurchase plan and a $250 million deal to acquire exclusive rights to the schizophrenia medication Saphris from Merck & Co. (MRK).
Altogether, it could be quite a boon for Forest�� bottom line. Leerink Swann analyst Seamus Fernandez raised his per share earnings estimate for 2015 and 2016 to $2.89 and $3.24 respectively from the previous $1.87 and $1.19. Fernandez writes:
We see several potential accretive Saphris-like opportunities for FRX particularly as companies like MRK partner or exit cost-intensive primary care/specialty categories (e.g., respiratory, antibiotics/antifungal, cardiology, GI, CNS). Incorporating these changes (and assuming no impact to sales ests of FRX’s existing portfolio), our new DCF valuation increases to $63/shr.
Hot High Dividend Companies To Own For 2015: Keryx Biopharmaceuticals Inc.(KERX)
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company?s products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types. The company is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease o n dialysis. Keryx Biopharmaceuticals, Inc. has commercial license agreements with Zentaris AG for the development of KRX-0401; Panion & BF Biotech, Inc. for the development and marketing of Zerenex; and Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. The company was founded in 1997 and is based in New York, New York.
Advisors' Opinion:- [By StockMatusow]
Keryx Biopharmaceuticals (KERX) is another company which did an offering that was received very well by investors. Keryx is a company that works on developing and commercializing novel therapies for the treatment of renal disease. On January 30, 2013, Keryx offered 8,234,000 shares priced at $8.49 per share. The offering was quickly bought by investors and continued to run higher.
